India: Pharmaceutical and Biotechnology Opportunities

Dec. 27, 2007 - PRLog -- The report provides an overview of the Indian pharma and biotech market, and answers the following key questions:

Who are the key players in the Indian pharmaceutical market?
How has the Indian regulatory environment changed?
What R&D collaborative opportunities are available?
How can companies engage with India for collaboration?
What are the leading R&D companies in India doing in collaborative R&D?
Readers will gain an analysis of the regulatory environment, insights into collaborative opportunities and detailed information on the key companies, clusters and government initiatives.

This report is a valuable resource for use by all those developing company strategy and direction in this key emerging market.

'India: Pharmaceutical and biotechnology opportunities' is based on the December 2004 report 'India: The emerging R&D collaborative opportunity'. The new report includes additional sections on the Indian Patents Act 2005, the Indian pharmaceutical policy, an overview of Department of Biotechnology initiatives, including details of biotechnology parks, and an all new set of profiles on life science research institutes.

The profiles section of 'India: Pharmaceutical and biotechnology opportunities' contains updated profiles and contact details on key companies.


 


1. Global collaborative R&D trends .
1.1. Falling R&D productivity .
1.1.1. Strategies adopted by global pharmaceutical companies to counter falling R&D productivity
1.2. Look East trend

2. The Indian pharmaceutical industry
2.1. Overview
2.2. Market assessment
2.3. Key players in the Indian pharmaceutical market

3. An analysis of the regulatory environment and its implications for R&D
3.1. Regulation in the Indian pharmaceutical industry: A historical perspective
3.2. The changing regulatory environment in India-Advantage R&D
3.3. An analysis of India's changing regulatory framework
3.3.1. Indian Patent Act, 1970
3.3.2. Patents Amendment Act, 2002
3.3.3. The Patents Amendment Ordinance, 2004
3.3.4. Indian Patents (Amendment) Act, 2005
3.3.5. New pharmaceutical policy (2006): Focus on R&D
3.3.5.1. Definitions of R&D
3.3.5.2. Technology upgrade funding
3.4. Response of MNCs to the changing regulatory environment
3.5. Implications for the Indian pharmaceutical industry
3.5.1. Collaborative and contract research and development
3.5.2. In- and out-licensing innovations

4. Collaborative R&D opportunities in India
4.1. Overview
4.2. Engagement models for licensing/purchasing innovation
4.3. Engagement models for contracting research services
4.4. NCE and NDDS research
4.5. Biopharma & drug discovery
4.5.1. Indian biopharma industry
4.5.1.1. Market size estimates: Indian biopharma industry
4.5.1.2. Indian biopharma industry: Vaccines segment
4.5.1.3. Indian biopharma industry: Therapeutics segment
4.5.1.4. Indian biopharma industry: Diagnostics segment
4.5.2. Drug discovery services
4.5.3. Indian biotechnology: Initiatives by the Department of Biotechnology
4.5.3.1. National Biotechnology Development Strategy
4.5.3.1.1. Fiscal and trade policy initiatives
4.5.3.1.2. Financial incentives
4.5.3.1.3. Biotechnology parks
4.5.3.1.4. Regulatory mechanisms
4.5.3.1.5. Create a cadre of resource persons
4.5.3.1.6. Empowering a judiciary
4.5.3.1.7. Industrial mechanisms for strengthening public trust
4.5.3.1.8. Single window
4.5.3.1.9. Innovation
4.5.3.1.10. Strengthening technology transfer capacity
4.5.3.1.11 National Task Force on Education & Training
4.5.3.1.12 Needs assessment
4.5.3.2. Stem cell research policy
4.5.4. Major recent developments in biotechnology
4.6. Bioinformatics.
4.6.1. Market size estimates of Indian bioinformatics industry
4.6.2. Bioinformatics companies in India
4.6.3. Bioinformatics policy of India
4.6.4. Major recent developments in bioinformatics
4.7. Clinical research
4.7.1. Market size estimates of the Indian clinical research industry
4.7.2. Clinical trials: MNC focus on India
4.7.3. Government initiatives to boost clinical research in India
4.7.4. Outsourcing clinical data management to India
4.7.4.1. CROs
4.7.4.2. IT-pharmaceutical ventures
4.7.4.3. Other IT/ITES companies' bio-initiatives

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=20062

# # #

bharatbook.com, a leading information aggregator, facilitates and supports the business information needs for market research , corporate / strategic planning by providing the latest information in the form of reports, journals, magazines and databases on varied industries like automotive, oil and gas, shipping, textiles, pharmaceuticals, energy, banking, finance, insurance, risk management

Website: www.bharatbook.com